Clozapina «brand» e clozapina generica nel trattamento della schizofrenia farmacoresistente: Bioequivalenza ed intercambiabilità

Translated title of the contribution: Brand-name versus generic clozapine for the treatment of resistant schizophrenia: Bioequivalence and interchangeability issues

Enrico Lattuada, F. Cocchi, M. Rossattini, A. Soldarini, G. Gentilini, F. Dorigatti, R. Cavallaro

Research output: Contribution to journalArticle

Abstract

A generic formulation of clozapine became recently available in Italy, along with doubts on its use, stemming from conflicting American studies on its efficacy and bioequivalence. Aim of this study was to assess possible changes of clinical response and plasma level of clozapine and N-desmethylclozapine in a sample of chronic schizophrenic patients. 41 patients with resistant schizophrenia or intolerant to classical antipsychotic treatment were assessed in this open study before and after switching from the brand (Leponex®) to the generic formulation (Clozapina Chiesi). Before and after 4 weeks from abrupt formulation cross-over, psychopathology was assessed by means of the Brief Psychiatric Rating Scale. Clozapine and N-desmethylclozapine plasma levels were measured by reverse phase HPLC. We found no significant differences in clinical status and plasma levels across the two formulations, all patients maintained response and tolerability profile.

Original languageItalian
Pages (from-to)267-271
Number of pages5
JournalItalian Journal of Psychopathology
Volume10
Issue number2
Publication statusPublished - Jun 2004

Fingerprint

Therapeutic Equivalency
norclozapine
Clozapine
Names
Schizophrenia
Brief Psychiatric Rating Scale
Therapeutics
Psychopathology
Italy
Antipsychotic Agents
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Clozapina «brand» e clozapina generica nel trattamento della schizofrenia farmacoresistente : Bioequivalenza ed intercambiabilità. / Lattuada, Enrico; Cocchi, F.; Rossattini, M.; Soldarini, A.; Gentilini, G.; Dorigatti, F.; Cavallaro, R.

In: Italian Journal of Psychopathology, Vol. 10, No. 2, 06.2004, p. 267-271.

Research output: Contribution to journalArticle

Lattuada, E, Cocchi, F, Rossattini, M, Soldarini, A, Gentilini, G, Dorigatti, F & Cavallaro, R 2004, 'Clozapina «brand» e clozapina generica nel trattamento della schizofrenia farmacoresistente: Bioequivalenza ed intercambiabilità', Italian Journal of Psychopathology, vol. 10, no. 2, pp. 267-271.
Lattuada, Enrico ; Cocchi, F. ; Rossattini, M. ; Soldarini, A. ; Gentilini, G. ; Dorigatti, F. ; Cavallaro, R. / Clozapina «brand» e clozapina generica nel trattamento della schizofrenia farmacoresistente : Bioequivalenza ed intercambiabilità. In: Italian Journal of Psychopathology. 2004 ; Vol. 10, No. 2. pp. 267-271.
@article{ff5544dcfcd241de84b5527e6059208c,
title = "Clozapina «brand» e clozapina generica nel trattamento della schizofrenia farmacoresistente: Bioequivalenza ed intercambiabilit{\`a}",
abstract = "A generic formulation of clozapine became recently available in Italy, along with doubts on its use, stemming from conflicting American studies on its efficacy and bioequivalence. Aim of this study was to assess possible changes of clinical response and plasma level of clozapine and N-desmethylclozapine in a sample of chronic schizophrenic patients. 41 patients with resistant schizophrenia or intolerant to classical antipsychotic treatment were assessed in this open study before and after switching from the brand (Leponex{\circledR}) to the generic formulation (Clozapina Chiesi). Before and after 4 weeks from abrupt formulation cross-over, psychopathology was assessed by means of the Brief Psychiatric Rating Scale. Clozapine and N-desmethylclozapine plasma levels were measured by reverse phase HPLC. We found no significant differences in clinical status and plasma levels across the two formulations, all patients maintained response and tolerability profile.",
keywords = "Brand-name clozapine Generic clozapine, Clozapine, Resistant schizophrenia, Schizophrenia",
author = "Enrico Lattuada and F. Cocchi and M. Rossattini and A. Soldarini and G. Gentilini and F. Dorigatti and R. Cavallaro",
year = "2004",
month = "6",
language = "Italian",
volume = "10",
pages = "267--271",
journal = "Giornale Italiano di Psicopatologia",
issn = "1592-1107",
publisher = "Pacini Editore s.r.l.",
number = "2",

}

TY - JOUR

T1 - Clozapina «brand» e clozapina generica nel trattamento della schizofrenia farmacoresistente

T2 - Bioequivalenza ed intercambiabilità

AU - Lattuada, Enrico

AU - Cocchi, F.

AU - Rossattini, M.

AU - Soldarini, A.

AU - Gentilini, G.

AU - Dorigatti, F.

AU - Cavallaro, R.

PY - 2004/6

Y1 - 2004/6

N2 - A generic formulation of clozapine became recently available in Italy, along with doubts on its use, stemming from conflicting American studies on its efficacy and bioequivalence. Aim of this study was to assess possible changes of clinical response and plasma level of clozapine and N-desmethylclozapine in a sample of chronic schizophrenic patients. 41 patients with resistant schizophrenia or intolerant to classical antipsychotic treatment were assessed in this open study before and after switching from the brand (Leponex®) to the generic formulation (Clozapina Chiesi). Before and after 4 weeks from abrupt formulation cross-over, psychopathology was assessed by means of the Brief Psychiatric Rating Scale. Clozapine and N-desmethylclozapine plasma levels were measured by reverse phase HPLC. We found no significant differences in clinical status and plasma levels across the two formulations, all patients maintained response and tolerability profile.

AB - A generic formulation of clozapine became recently available in Italy, along with doubts on its use, stemming from conflicting American studies on its efficacy and bioequivalence. Aim of this study was to assess possible changes of clinical response and plasma level of clozapine and N-desmethylclozapine in a sample of chronic schizophrenic patients. 41 patients with resistant schizophrenia or intolerant to classical antipsychotic treatment were assessed in this open study before and after switching from the brand (Leponex®) to the generic formulation (Clozapina Chiesi). Before and after 4 weeks from abrupt formulation cross-over, psychopathology was assessed by means of the Brief Psychiatric Rating Scale. Clozapine and N-desmethylclozapine plasma levels were measured by reverse phase HPLC. We found no significant differences in clinical status and plasma levels across the two formulations, all patients maintained response and tolerability profile.

KW - Brand-name clozapine Generic clozapine

KW - Clozapine

KW - Resistant schizophrenia

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=14644414783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644414783&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:14644414783

VL - 10

SP - 267

EP - 271

JO - Giornale Italiano di Psicopatologia

JF - Giornale Italiano di Psicopatologia

SN - 1592-1107

IS - 2

ER -